© 2003 Robert A. Freitas Jr. All Rights Reserved.

Robert A. Freitas Jr., Nanomedicine, Volume IIA: Biocompatibility, Landes Bioscience, Georgetown, TX, 2003

References 3300-3399

3300. E. Kownatzki, E. Liehl, H. Aschauer, S. Uhrich, “Inhibition of chemotactic migration of human neutrophilic granulocytes by recombinant human granulocyte-macrophage colony-stimulating factor,” Immunopharmacology 19(March-April 1990):139-143.

3301. Lynn E. Hancock, Michael S. Gilmore, “Pathogenicity of Enterococci,” in Vincent Fischetti, Richard Novick, Joseph Ferretti, Dan Portnoy, Julian Rood, eds., Gram-Positive Pathogens, ASM Press, Washington, DC, 2000; http://www.enterococcus.ouhsc.edu/lynn_revirew.asp

3302. Kenneth Todar, “Evasion of Host Phagocytic Defenses,” University of Wisconsin-Madison; http://www.bact.wisc.edu/microtextbook/disease/evadephago.html

3303. C.G. Gemmell, “Changes in expression of bacterial surface antigens induced by antibiotics and their influence on host defenses,” Pathol. Biol. (Paris) 35(December 1987):1377-1381.

3304. “Haemophilus influenza (Hib) – Virulence and Evasion Strategies,” 1999; http://cweb.middlebury.edu/s99/bi330a/projects/Balamotis/virulent/virulent.shtml

3305. C.C. Chen, P.P. Cleary, “Complete nucleotide sequence of the streptococcal C5a peptidase gene of Streptococcus pyogenes,” J. Biol. Chem. 265(25 February 1990):3161-3167; P.P. Cleary, J. Peterson, C. Chen, C. Nelson, “Virulent human strains of group G streptococci express a C5a peptidase enzyme similar to that produced by group A streptococci,” Infect. Immun. 59(July 1991):2305-2310; P.P. Cleary, U. Prahbu, J.B. Dale, D.E. Wexler, J. Handley, “Streptococcal C5a peptidase is a highly specific endopeptidase,” Infect. Immun. 60(December 1992):5219-5223.

3306. A. Berge, L. Bjorck, “Streptococcal cysteine proteinase releases biologically active fragments of streptococcal surface proteins,” J. Biol. Chem. 270(28 April 1995):9862-9867.

3307. S.B. Galsworthy, “Bacteria IV: Pus-forming Bacteria,” Bio221aF99, Lecture 12, 1999; http://bio221.mni.uwo.ca/W2000/lectures/Lecture12_99.html

3308. M.R. Wessels, A.E. Moses, J.B. Goldberg, T.J. DiCesare, “Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci,” Proc. Natl. Acad. Sci. (USA) 88(1 October 1991):8317-8321.

3309. “Streptococcus pyogenes”; http://bifido.net/HTML-data/micro/IStreptococcus%20pyogenes-I.htm

3310. D. Kingston, L.E. Glynn, ‘A cross-reaction between Str. pyogenes and human fibroblasts, endothelial cells and astrocytes,” Immunology 21(December 1971):1003-1016.

3311. K. Krisher, M.W. Cunningham, “Myosin: a link between streptococci and heart,” Science 227(25 January 1985):413-415.

3312. D.R. Haynes, D.G. Harkin, L.P. Bignold, M.J. Hutchens, S.M. Taylor, D.P. Fairlie, “Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist,” Biochem. Pharmacol. 60(1 September 2000):729-733.

3313. R.R. Pfister, J.L. Haddox, J.E. Blalock, C.I. Sommers, L. Coplan, M. Villain, “Synthetic complementary peptides inhibit a neutrophil chemoattractant found in the alkali-injured cornea,” Cornea 19(May 2000):384-389.

3314. L. Harvath, C.E. McCall, D.A. Bass, L.C. McPhail, “Inhibition of human neutrophil chemotaxis by the protein kinase inhibitor, 1-(5-isoquinolinesulfonyl) piperazine,” J. Immunol. 139(1 November 1987):3055-3061.

3315. Y. Choi, L.F. Chuang, K.M. Lam, H.F. Kung, J.M. Wang, B.I. Osburn, R.Y. Chuang, “Inhibition of chemokine-induced chemotaxis of monkey leukocytes my mu-opioid receptor agonists,” In Vivo 13(September-October 1999):389-396.

3316. D.K. Litwin, A.K. Wilson, S.I. Said, “Vasoactive intestinal polypeptide (VIP) inhibits rat alveolar macrophage phagocytosis and chemotaxis in vitro,” Regul. Pept. 40(2 July 1992):63-74.

3317. S. Suzuki, T. Tanita, H. Kubo, Y. Ashino, M. Chida, K. Koike, S. Fujimura, “Stimulation of pulmonary intravascular macrophages increases microvascular permeability in awake sheep,” Tohoku J. Exp. Med. 169(February 1993):121-130.

3318. J. Zagorski, S.M. Wahl, “Inhibition of acute peritoneal inflammation in rats by a cytokine-induced neutrophil chemoattractant receptor antagonist,” J. Immunol. 159(1 August 1997):1059-1062.

3319. M. De la Fuente, M. Carrasco, A. Hernanz, “Modulation of human neutrophil function in vitro by gastrin,” J. Endocrinol. 153(June 1997):475-483.

3320. K.T. Hall, L. Boumsell, J.L. Schultze, V.A. Boussiotis, D.M. Dorfman, A.A. Cardoso, A. Bensussan, L.M. Nadler, G.J. Freeman, “Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation,” Proc. Natl. Acad. Sci. (USA) 93(15 October 1996):11780-11785.

3321. S. Delaire, A. Elhabazi, A. Bensussan, L. Boumsell, “CD100 is a leukocyte semaphorin,” Cell. Mol. Life Sci. 54(November 1998):1265-1276.

3322. T. Furuyama et al, “Identification of a novel transmembrane semaphorin expressed on lymphocytes,” J. Biol. Chem. 271(27 December 1996):33376-33381.

3323. T. Mine, K. Harada, T. Matsumoto, H. Yamana, K. Shirouzu, K. Itoh, A. Yamada, “CDw108 expression during T-cell development,” Tissue Antigens 55(May 2000):429-436.

3324. M.R. Comeau et al, “A poxvirus-encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR,” Immunity 8(April 1998):473-482.

3325. N. Jaulin, M. Appel, C. Passirani, G. Barratt, D. Labarre, “Reduction of the uptake by a macrophagic cell line of nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate),” J. Drug Target. 8(2000):165-172.

3326. R. Gref, M. Luck, P. Quellec, M. Marchand, E. Dellacherie, S. Harnisch, T. Blunk, R.H. Muller, “Stealth corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption,” Colloids Surf. B Biointerfaces 18(1 October 2000):301-313.

3327. H. Kawaguchi, N. Koiwai, Y. Ohtsuka, M. Miyamoto, S. Sasakawa, “Phagocytosis of latex particles by leucocytes. I. Dependence of phagocytosis on the size and surface potential of particles,” Biomaterials 7(January 1986):61-66.

3328. R. Kapur, J. Lilien, G.L. Picciolo, J. Black, “Human monocyte morphology is affected by local substrate charge heterogeneity,” J. Biomed. Mater. Res. 32(September 1996):133-142. See also: R. Kapur, J.M. Calvert, A.S. Rudolph, “Electrical, chemical, and topological addressing of mammalian cells with microfabricated systems,” J. Biomech. Eng. 121(February 1999):65-72.

3329. Per-Arne Oldenborg, Alex Zheleznyak, Yi-Fu Fang, Carl F. Lagenaur, Hattie D. Gresham, Frederik P. Lindberg, “Role of CD47 as a Marker of Self on Red Blood Cells,” Science 288(16 June 2000):2051-2054, 1945-1946 (discussion); P.A. Oldenborg, H.D. Gresham, F.P. Lindberg, “CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis,” J. Exp. Med. 193(2 April 2001):855-862.

3330. E. Whitnack, A.L. Bisno, E.H. Beachey, “Hyaluronate capsule prevents attachment of group A streptococci to mouse peritoneal macrophages,” Infect. Immun. 31(March 1981):985-991.

3331. F. d’Herelle, The Bacteriophage: Its Role in Immunity, Williams & Wilkins, Baltimore MD, 1922. Translated by G.H. Smith. See also: F. d’Herelle, The Bacteriophage and Its Clinical Applications, Thomas, Baltimore MD, 1930; A. Raiga-Clemenceau, “d’Herelle’s bacteriophage and its therapeutic property,” Sem. Hop. Ther. 50(March 1974):229-231 (In French).

3332. A.D. Doerman, “Lysis and lysis inhibition with Escherichia coli bacteriophage,” J. Bacteriol. 55(1948):257-275.

3333. M.R. Geier, M.E. Trigg, C.R. Merril, “Fate of bacteriophage lambda in non-immune germ-free mice,” Nature 246(23 November 1973):221-223.

3334. H.W. Smith, R.B. Huggins, “Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics,” J. Gen. Microbiol. 128(February 1982):307-318.

3335. A.B. Chernomordik, “Bacteriophages and their therapeutic-prophylactic use,” Med. Sestra. 48(June 1989):44-47. In Russian.

3336. J.S. Soothill, “Treatment of experimental infections of mice with bacteriophages,” J. Med. Microbiol. 37(October 1992):258-261.

3337. J.S. Soothill, “Bacteriophage prevents destruction of kin grafts by Pseudomonas aeruginosa,” Burns 20(June 1994):209-211.

3338. C.R. Merril, B. Biswas, R. Carlton, N.C. Jensen, G.J. Creed, S. Zullo, S. Adhya, “Long-circulating bacteriophage as antibacterial agents,” Proc. Natl. Acad. Sci. (USA) 93(16 April 1996):3188-3192.

3339. J. Lederberg, “Smaller fleas .. ad infinitum: therapeutic bacteriophage redux,” Proc. Natl. Acad. Sci. (USA) 93(16 April 1996):3167-3168.

3340. P.A. Barrow, J.S. Soothill, “Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential,” Trends Microbiol. 5(July 1997):268-271.

3341. J. Alisky, K. Iczkowski, A. Rapoport, N. Troitsky, “Bacteriophages show promise as antimicrobial agents,” J. Infect. 36(January 1998):5-15.

3342. B.I. Koerner, “Return of a killer. Phages may once again fight tough bacterial infections,” U.S. News & World Rep. 125(2 November 1998):51-52.

3343. R.M. Carlton, “Phage therapy: past history and future prospects,” Arch. Immunol. Ther. Exp. (Warsz) 47(1999):267-274.

3344. R.J. Payne, D. Phil, V.A. Jansen, “Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals,” Clin. Pharmacol. Ther. 68(September 2000):225-230.

3345. K. Kwiatkowska, A. Sobota, “Signaling pathways in phagocytosis,” Bioessays 21(May 1999):422-431.

3346. O. Dorseuil, M.T. Quinn, G.M. Bokoch, “Dissociation of Rac translocation from p47phox/p67phox movements in human neutrophils by tyrosine kinase inhibitors,” J. Leukoc. Biol. 58(July 1995):108-113.

3347. K. Takaishi, T. Sasaki, Y. Takai, “Cell motility assay and inhibition by Rho-GDP dissociation inhibitor,” Methods Enzymol. 256(1995):336-347.

3348. M.C. Dagher, A. Fuchs, N. Bourmeyster, A. Jouan, P.V. Vignais, “Small G proteins and the neutrophil NADPH oxidase,” Biochemie 77(1995):651-660.

3349. S. Lloret, J.J. Moreno, “Role of kinases and G-proteins on arachidonate release induced by zymosan in mouse peritoneal macrophages,” Int. J. Biochem. Cell Biol. 28(April 1996):465-472.

3350. V. Diatchuk, O. Lotan, V. Koshkin, P. Wikstroem, E. Pick, “Inhibition of NADPH oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related compounds,” J. Biol. Chem. 272(16 May 1997):13292-13301.

3351. D.J. Seastone, L. Zhang, G. Buczynski, P. Rebstein, G. Weeks, G. Spiegelman, J. Cardelli, “The small Mr Ras-like GTPase Rap1 and the phospholipase C pathway act to regulate phagocytosis in Dictyostelium discoideum,” Mol. Biol. Cell 10(February 1999):393-406.

3352. Y.S. Bae, Y. Kim, Y. Kim, J.H. Kim, P.G. Suh, S.H. Ryu, “Trp-Lys-Tyr-Met-Val-D-Met is a chemoattractant for human phagocytic cells,” J. Leukoc. Biol. 66(December 1999):915-922.

3353. J.M. Watson, T.W. Harding, V. Golubovskaya, J.S. Morris, D. Hunter, X. Li, J.S. Haskill, H.S. Earp, “Inhibition of the calcium-dependent tyrosine kinase (CADTK) blocks monocyte spreading and motility,” J. Biol. Chem. 276(2 February 2001):3536-3542.

3354. S.S. Buys, J. Kaplan, “Effect of phagocytosis on receptor distribution and endocytic activity in macrophages,” J. Cell Physiol. 131(June 1987):442-449.

3355. M. Garcia Gil, M. Sanchez Crespo, “Dansylcadaverine and rimantadine inhibition of phagocytosis, PAF-acether release, and phosphatidylcholine synthesis in human polymorphonuclear leukocytes,” Immunopharmacology 6(December 1983):317-325.

3356. P.J. Davies, M.M. Cornwell, J.D. Johnson, A. Reggianni, M. Myers, M.P. Murtaugh, “Studies on the effects of dansylcadaverine and related compounds on receptor-mediated endocytosis in cultured cells,” Diabetes Care 7(May-June 1984):34-41 (Suppl 1).

3357. L.A. Allen, A. Aderem, “Mechanisms of phagocytosis,” Curr. Opin. Immunol. 8(February 1996):36-40.

3358. E.Z. Tomei, F.L. Renaud, “Effect of morphine on Fc-mediated phagocytosis by murine macrophages in vitro,” J. Neuroimmunol. 74(April 1997):111-116.

3359. R. Gomez-Flores, J.L. Suo, R.J. Weber, “Suppression of splenic macrophage functions following acute morphine action in the rat mesencephalon periaqueductal gray,” Brain Behav. Immun. 13(September 1999):212-224.

3360. W.S. Hu, C.C. Muscoplat, “Lidocaine: effect on phagocytosis and purification of monocytes in bovine peripheral blood,” Am. J. Vet. Res. 41(March 1980):447-449.

3361. A.R. Jurjus, D. Jarrush-Saadeh, C. Nassar, “Modulation of some human mononuclear cells activities by procaine,” Middle East J. Anesthesiol. 9(June 1988):417-428.

3362. H. Morland, B. Morland, “Different effects of ethanol on particle phagocytosis via different receptors in human monocytes,” APMIS 97(September 1989):853-857.

3363. I. Lautenschlager, H. Vaananen, E. Kulonen, “Qualitative study on the Kupffer cells in the liver of ethanol- and carbon tetrachloride-treated rats,” Acta Pathol. Microbiol. Immunol. Scand. C 90(December 1982):347-351.

3364. Y. Matsumoto, D.H. Johnson, “Dexamethasone decreases phagocytosis by human trabecular meshwork cells in situ,” Invest. Ophthalmol. Vis. Sci. 38(August 1997):1902-1907.

3365. M. Carrasco, M. Del Rio, A. Hernanz, M. De la Fuente, “Inhibition of human neutrophil functions by sulfated and nonsulfated cholecystokinin octapeptides,” Peptides 18(1997):415-422.

3366. R.J. Smith, “Modulation of phagocytosis by and lysomal enzyme secretion from guinea-pig neutrophils: effect of nonsteroid anti-inflammatory agents and prostaglandins,” J. Pharmacol. Exp. Ther. 200(March 1977):647-657.

3367. P.S. Hiemstra, A. Annema, E.F. Schippers, R. van Furth, “Pertussis toxin partially inhibits phagocytosis of immunoglobulin G-opsonized Staphylococcus aureus by human granulocytes but does not affect intracellular killing,” Infect. Immun. 60(January 1992):202-205.

3368. J. O’Brien, A. Friedlander, T. Dreier, J. Ezzell, S. Leppla, “Effects of anthrax toxin components on human neutrophils,” Infect. Immun. 47(January 1985):306-310.

3369. D.L. Confer, J.W. Eaton, “Pathogen-host jujitsu: phagocyte impotence caused by internalized bacterial adenylate cyclase,” Trans. Assoc. Am. Physicians 95(1982):1-7; “Phagocyte impotence caused by an invasive bacterial adenylate cyclase,” Science 217(3 September 1982):948-950; “Bordetella adenylate cyclase: host toxicity and diagnostic utility,” Dev. Biol. Stand. 61(1985):3-10.

3370. G.F. Gerberick, W.G. Sorenson, D.M. Lewis, “The effects of T-2 toxin on alveolar macrophage function in vitro,” Environ. Res. 33(February 1984):246-260.

3371. N.K. Mohapatra, J.F. Roberts, “In vitro effect of aflatoxin B1 on rat liver macrophages (Kupffer cells),” Toxicol. Lett. 29(December 1985):177-181; V. Cosumano, G.B. Costa, R. Trifiletti, R.A. Merendino, G. Mancuso, “Functional impairment of rat Kupffer cells induced by aflatoxin B1 and its metabolites,” FEMS Immunol. Med. Microbiol. 10(January 1995):151-155.

3372. A. Shukla, L. Berglund, L.P. Nielsen, S. Nielsen, H.J. Hoffmann, R. Dahl, “Regulated exocytosis in immune function: are SNARE-proteins involved?” Respir. Med. 94(January 2000):10-17.

3373. A.L. Shiau, C.L. Wu, “The inhibitory effect of Staphylococcus epidermidis slime on the phagocytosis of murine peritoneal macrophages is interferon-independent,” Microbiol. Immunol. 42(1998):33-40.

3374. L.G. Visser, E. Seijmonsbergen, P.H. Nibbering, P.J. van den Broek, R. van Furth, “Yops of Yersinia enterocolitica inhibit receptor-dependent superoxide anion production by human granulocytes,” Infect. Immun. 67(March 1999):1245-1250.

3375. V.T. Lee, O. Schneewind, “Type III machines of pathogenic yersiniae secrete virulence factors into the extracellular milieu,” Mol. Microbiol. 31(March 1999):1619-1629; Mole. Microbiol. 34(October 1999):196 (erratum).

3376. P.A. Valberg, J.D. Brain, D. Kane, “Effects of colchicine or cytochalasin B on pulmonary macrophage endocytosis in vivo,” J. Appl. Physiol. 50(March 1981):621-629.

3377. J.E. Kaplan, T.M. Saba, “Humoral deficiency and reticuloendothelial depression after traumatic shock,” Am. J. Physiol. 230(January 1976):7-14; D.J. Loergering, J.E. Kaplan, T.M. Saba, “Correlation of plasma lysosomal enzyme levels with hepatic reticuloendothelial function after trauma,” Proc. Soc. Exp. Biol. Med. 152(May 1976):42-46.

3378. T.M. Saba, E. Jaffe, “Plasma fibronectin (opsonic glycoprotein): its synthesis by vascular endothelial cells and role in cardiopulmonary integrity after trauma as related to reticuloendothelial function,” Am. J. Med. 68(April 1980):577-594.

3379. T.M. Saba, T.G. Antikatzides, “Decreased resistance to intravenous tumour-cell challenge during reticuloendothelial depression following surgery,” Br. J. Cancer 34(October 1976):381-389.

3380. C.L. Atanassov, C.D. Muller, S. Dumont, G. Rebel, P. Poindron, N. Seiler, “Effect of ammonia on endocytosis and cytokine production by immortalized human microglia and astroglia cells,” Neurochem. Int. 27(October-November 1995):417-424.

3381. C.L. Atanassov, C.D. Muller, S. Sarhan, B. Knodgen, G. Rebel, N. Seiler, “Effect of ammonia on endocytosis, cytokine production and lysosomal enzyme activity of a microglial cell line,” Res. Immunol. 145(May 1994):277-288.

3382. J.A. Graham, D.E. Gardner, M.D. Waters, D.L. Coffin, “Effect of trace metals on phagocytosis by alveolar macrophages,” Infect. Immun. 11(June 1975):1278-1283.

3383. Elizabeth Husztik, George Lazar, Stephen Szilagyi, “Study on the Mechanism of Kupffer Cell Phagocytosis Blockade Induced by Gadolinium Chloride,” in E. Wisse, D.L. Knook, eds., Kupffer Cells and Other Liver Sinusoidal Cells, Elsevier/North-Holland Biomedical Press, New York, 1977, pp. 387-395.

3384. J.A. Kamps, H.W. Morselt, G.L. Scherphof, “Uptake of liposomes containing phosphatidylserine by liver cells in vivo and by sinusoidal liver cells in primary culture: in vivo - in vitro differences,” Biochem. Biophys. Res. Commun. 256(5 March 1999):57-62.

3385. S.J. Riggi, N.R. di Luzio, “Hepatic function during reticuloendothelial hyperfunction and hyperplasia,” Nature 193(1962):1292-1294.

3386. S.J. Chadwick, M. Aldridge, H.A. Dudley, “Detection of reticulo-endothelial blockade with low-dose test agent,” Br. J. Exp. Pathol. 66(August 1985):483-491.

3387. S.J. Suchard, V. Hinkovska-Galcheva, P.J. Mansfield, L.A. Boxer, J.A. Shayman, “Ceramide inhibits IgG-dependent phagocytosis in human polymorphonuclear leukocytes,” Blood 89(15 March 1997):2139-2147.

3388. H. Bos, W. de Souza, “Phagocytosis of yeast: a method for concurrent quantification of binding and internalization using differential interference contrast microscopy,” J. Immunol. Methods 238(21 April 2000):29-43.

3389. B. Brett Finlay, Pascale Cossart, “Exploitation of mammalian host cell functions by bacterial pathogens,” Science 276(2 May 1997):718-725.

3390. W. Pruzanski, S. Saito, S. Stylianos, H. Jacobs, “Influence of monoclonal IgM cold agglutinins on adhesiveness, phagocytosis, and bactericidal activity on human granulocytes and monocytes,” Inflammation 13(April 1989):201-209.

3391. J.M. te Koppele, R.G. Thurman, “Phagocytosis by Kupffer cells predominates in pericentral regions of the liver lobule,” Am. J. Physiol. 259(November 1990):G814-G821.

3392. H. Ji, W. Shu, F.T. Burling, S. Jiang, M. Lu, “Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion,” J. Virol. 73(October 1999):8678-8586.

3393. R.M. Epand, R.F. Epand, C.D. Richardson, P.L. Yeagle, “Structural requirements for the inhibition of membrane fusion by carbobenzoxy-D-Phe-Phe-Gly,” Biochim. Biophys. Acta 1152(10 October 1993):128-134.

3394. J. Corver, R. Bron, H. Snippe, C. Kraaijeveld, J. Wilschut, “Membrane fusion activity of Semliki Forest virus in a liposomal model system: specific inhibition by Zn2+ ions,” Virology 238(10 November 1997):14-21.

3395. K.A. Staschke, S.D. Hatch, J.C. Tang, W.J. Hornback, J.E. Munroe, J.M. Colacino, M.A. Muesing, “Inhibition of influenza virus hemagglutinin-mediated membrane fusion by a compound related to podocarpic acid,” virology 248(1 September 1998):264-274.

3396. T.S. Stantchev, C.C. Broder, “Consistent and significant inhibition of human immunodeficiency virus type 1 envelope-mediated membrane fusion by beta-chemokines (RANTES) in primary human macrophages,” J. Infect. Dis. 182(July 2000):68-78.

3397. S. Gunther-Ausborn, A. Praetor, T. Stegmann, “Inhibition of influenza-induced membrane fusion by lysophosphatidylcholine,” J. Biol. Chem. 270(8 December 1995):29279-29285; P.L. Yeagle, F.T. Smith, J.E. Young, T.D. Flanagan, “Inhibition of membrane fusion by lysophosphatidylcholine,” Biochemistry 33(22 February 1994):1820-1827.

3398. L. Liu, J.Q. Tao, H.L. Li, U.J. Zimmerman, “Inhibition of lung surfactant secretion from alveolar type II cells and annexin II tetramer-mediated membrane fusion by phenothiazines,” Arch. Biochem. Biophys. 342(15 June 1997):322-328.

3399. J. Aggeler, Z. Werb, “Initial events during phagocytosis by macrophages viewed from outside and inside the cell: membrane-particle interactions and clathrin,” J. Cell Biol. 94(September 1982):613-623.

Last updated on 16 April 2004